At a national level in Finland, the SII reimbursement level for insulins (A10A) remained at 100% throughout the follow‐up time in this study, but noninsulin diabetes medication (A10B) reimbursement level changed from 100% to 65% at the beginning of 2017.17, 18. Here, INS is linked to diabetes mellitus.